Lufotrelvir

Lufotrelvir
Legal status
Legal status	US: Investigational drug;
Identifiers
	IUPAC name [(3S)-3-[(2S)-2-[(4-methoxy-1H-indol-2-yl)formamido]-4-methylpentanamido]-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butoxy]phosphonic acid;
CAS Number	2468015-78-1;
PubChem CID	154699467;
DrugBank	DB16514;
UNII	XJ51YOB1SC;
KEGG	D12172;
ChEBI	CHEBI:173073;
CompTox Dashboard (EPA)	DTXSID501337108 ;
Chemical and physical data
Formula	C24H33N4O9P
Molar mass	552.521 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)COP(=O)(O)O)NC(=O)C2=CC3=C(N2)C=CC=C3OC;
	InChI InChI=1S/C24H33N4O9P/c1-13(2)9-18(28-24(32)19-11-15-16(26-19)5-4-6-21(15)36-3)23(31)27-17(10-14-7-8-25-22(14)30)20(29)12-37-38(33,34)35/h4-6,11,13-14,17-18,26H,7-10,12H2,1-3H3,(H,25,30)(H,27,31)(H,28,32)(H2,33,34,35)/t14-,17-,18-/m0/s1; Key:FQKALOFOWPDTED-WBAXXEDZSA-N;

Lufotrelvir (PF-07304814) is an antiviral drug developed by Pfizer which acts as a 3CL protease inhibitor.^[1] It is a prodrug with the phosphate group being cleaved in vivo to yield the active agent PF-00835231.^[2] Lufotrelvir is in human clinical trials for the treatment of COVID-19, and shows good activity against COVID-19 including several variant strains, but unlike the related drug nirmatrelvir it is not orally active and must be administered by intravenous infusion, and so has been the less favoured candidate for clinical development overall.^[3]^[4]^[5]

Quick Facts Legal status, Identifiers ...

[1]

[2]

[3]

[4]

[5]

Lufotrelvir

See also

References

Wikiwand - on